Context: Adipose tissue (AT) expansion occurs by hypertrophy and hyperplasia. Impaired hyperplasia, or adipogenesis, has been associated with obesity-related diseases.
T he distribution of adipose tissue (AT) in the body is a strong predictor of metabolic health risk. Abdominal adiposity [visceral AT (VAT) and subcutaneous abdominal (scABD)] is linked to obesity-related diseases, and lower body adiposity [gluteal and femoral (scFEM)] is associated with an improved metabolic profile (1) . These opposing associations with metabolic health have been attributed to intrinsic characteristics of adipose depots, although the mechanisms remain unclear.
AT expansion is necessary to accommodate chronic excess caloric intake and is characterized by enlargement of adipocyte size (hypertrophy) and by increasing preadipocyte and adipocyte numbers (hyperplasia). Evidence suggests that the manner of subcutaneous adipose expansion (hypertrophy vs hyperplasia) can influence metabolic health. Impaired adipogenesis, namely restricted hyperplasia, can lead to ectopic lipid deposition in the liver and skeletal muscle, contributing to the pathogenesis of insulin resistance and type 2 diabetes mellitus (2-4). Arner et al. (5) developed a morphology index, based on adipocyte size, to predict scABD cellularity in humans. They reported that greater hyperplastic expansion (lower morphology index) correlated with insulin sensitivity (5) . Collectively, these studies support the "AT expandability hypothesis," which postulates that a lack of hyperplasia results in the limited capacity of AT to expand and store fat, causing metabolic derangements (6) . In contrast, more recent observations by our laboratory (7) , and others (8) (9) (10) (11) , reported that an increased population of small adipocytes, suggesting hyperplastic expansion, is associated with metabolic syndrome. Previous analyses assessed AT dynamics primarily by assessing adipocyte size; however, these indirect measures do not encompass the in vivo microenvironment. Accordingly, the cellular mechanisms underlying in vivo adipose cell turnover (adipogenesis and adipocyte cell death) have not been elucidated.
Early studies proposed that adipocyte number in humans is determined during adolescence and remains unchanged during adulthood (12) (13) (14) . However, recent data have confirmed that adults constantly form and replace adipose cells (15, 16 ). Arner's group (5) demonstrated that the adipocyte morphology index was highly related to in vivo adipocyte turnover, as measured by the DNA incorporation of 14 C. To the best of our knowledge, to date, no study has directly assessed the relationship between quantitative measures of in vivo adipose cell kinetics and markers of metabolic health in humans.
Recently, we measured in vivo adipogenesis (i.e., replacement) in scABD and scFEM depots using an 8-week incorporation of deuterium ( 2 H), administered as 2 H 2 O (17), into the DNA of adipose cells in women with obesity (16) . We showed that in vivo preadipocyte and adipocyte formation was greater in the scFEM depot than in the scABD and that adipose cell kinetics correlated positively with body fat content. In the present study, we expanded our analysis to include more women to investigate how in vivo adipogenesis and turnover correlates with facets of metabolic health, including body composition, ectopic lipid, and insulin sensitivity. Given that AT depots are differentially associated with metabolic health and might expand differently in response to overfeeding (18), we analyzed scABD and scFEM depots. In contrast to the existing AT expandability hypothesis, our data have demonstrated that in vivo subcutaneous adipose cell kinetics correlate positively with body mass index (BMI) and VAT content and are negatively associated with insulin sensitivity in women with obesity.
Materials and Methods

Subject characteristics
Healthy women were recruited according to the following inclusion criteria: 18 to 40 years of age, BMI 27 to 38 kg/m 2 , fasting plasma glucose of #110 mg/dL, blood pressure (BP) of #140/90 mm Hg, the absence of major organ disease, normal urinary and blood laboratory test results (i.e., complete blood count, renal panel, electrolytes, and liver enzymes), weight stability for $3 months (63.2 kg), and no self-reported substantial changes in diet or physical activity in the previous month. The exclusion criteria included a history of diagnosed diabetes, heart disease, or liver disease; the chronic use of medications with potential metabolic effects; and the use of medications or surgical procedures that cause weight gain or loss. Subjects with HIV, hepatitis B, or hepatitis C infection were also excluded, as were pregnant or breastfeeding women. The institutional review board of Pennington Biomedical Research Center approved the protocol, and all subjects gave written, informed consent. The trial is registered with ClinicalTrials.gov (ClinicalTrials.gov identifier, NCT01748994). 
Study procedures
Anthropometric measures (height, metabolic weight, waist/hip ratio, mean BP [one-third (systolic BP 2 diastolic BP) + diastolic BP]) were taken at the start of the study. Fasting plasma total triglycerides, high-density lipoprotein, low-density lipoprotein, and total cholesterol were measured. After the 8-week 2 H-labeling period, the anthropometric measures were repeated. The change in body weight was calculated as the final weight (week 8) minus the initial weight (study start).
Body composition measures (week 8)
Dual-energy x-ray absorptiometry was performed using the Lunar iDXA (GE Healthcare, Little Chalfont, UK) to determine the total body fat. The scans were analyzed using the enCORE software, version 13.60.033 (GE Healthcare). The scABD AT and VAT volumes were defined and quantified using magnetic resonance imaging using a 3.0T scanner (Discovery 750w; GE Healthcare) by obtaining ;581 images from the dome of the liver to the pubic symphysis. The images were analyzed by a single trained analyst. Estimates of VAT and scABD AT volumes were converted to mass using an assumed density of 0.92 kg/L. The VAT/total abdominal AT (TAT) ratio reflects the percentage of abdominal fat that is VAT and is calculated as follows: VAT/(scABD AT + VAT).
Intramyocellular (IMCL) and extramyocellular (EMCL) lipid in the soleus and anterior tibialis skeletal muscles and intrahepatic lipid (IHL), were measured using proton magnetic resonance spectroscopy on a 3.0T whole body imaging and spectroscopy system (Discovery 750w system; GE Healthcare) using a commercially available 1 H body coil. The IMCL, EMCL, and IHL content were determined using the Java-based magnetic resonance user interface (19) , as previously described (20) (21) (22) . The IMCL, EMCL, and IHL peak areas are expressed relative to the peak area of a peanut oil phantom signal of known constant concentration, as previously described (23) . IMCL and EMCL data reflect the combination of soleus and anterior tibialis lipid.
Oral glucose tolerance test (week 8)
Insulin sensitivity was assessed using the 2-hour oral glucose tolerance test (OGTT) and calculated using the Matsuda index [10,000/square root of (fasting glucose 3 fasting insulin) 3 (mean OGTT glucose 3 mean OGTT insulin)] (24).
AT collection and isolation of adipocytes and preadipocytes (week 8)
AT biopsy specimens were collected using the Bergstrom and Mercedes lipoaspirate techniques under sterile conditions and local anesthesia. Samples were taken from the scABD region, between one-and two-thirds of the distance from the iliac spine to the umbilicus, and from the scFEM region, on the anterior aspect of the thigh, one-to two-thirds of the distance from the superior iliac spine to the patella. The tissue was immediately placed in sterile tubes for processing. The procedures were the same and the measurements were consistent for all biopsy collections.
scABD and scFEM tissues were treated with a HEPES/type 1 collagenase solution for 1 hour at 37°C to isolate the adipocytes and the stroma-vascular fraction (SVF) (25) . The adipocytes were purified by incubation with a cocktail of biotinylated antibodies against markers of endothelial cells (CD31; eBioscience; Thermo Fisher Scientific Life Sciences), hematopoietic cells (CD45; BioLegend, San Diego, CA), and mesenchymal stem cells (CD34; eBioscience) for 15 minutes at room temperature. The cells attached to these antibodies were bound by magnetic nanoparticles (EasySep; StemCell Technologies, Vancouver, BC, Canada), and immunopurified adipocytes were removed and retained. The adipocytes were flash frozen in liquid nitrogen and stored at 280°C until DNA extraction.
To isolate preadipocytes, a protocol was used to exploit their property to attach to plastic after short-term culture of the SVF (26) . The SVF was reconstituted in erythrocyte lysis buffer for 5 minutes at room temperature, centrifuged, reconstituted in 10% fetal bovine serum in a-minimal essential medium, and cultured for 6 hours. The nonadherent cells were washed from the culture plate with phosphate-buffered saline. The adherent preadipocytes were detached (0.25% trypsin/EDTA) and centrifuged, and the pellet was stored at 280°C until DNA extraction.
Collection of blood monocytes
Blood was collected in Ficoll-Paque solution, and the mononuclear fraction was removed after centrifugation. Monocytes were isolated as CD14 + cells using immune-magnetic beads (EasySep; StemCell Technologies).
DNA preparation
DNA was isolated from the adipocytes, preadipocytes, and blood monocytes using DNEasy microDNA extraction kits (Qiagen, Hilden, Germany). DNA was enzymatically hydrolyzed to free deoxyribonucleosides (27) , and hydrolysates were derivatized to pentafluorobenzyl hydroxylamine derivatives for gas chromatography mass spectrometry analysis.
Gas chromatographic/mass spectrometric analyses and calculation of fraction of new cells
The pentafluorobenzyl hydroxylamine derivatives were analyzed for incorporation of 2 H 2 O on an Agilent 6890/5973 gas chromatograph/mass spectrometer (Agilent, Santa Clara, CA) equipped with a 30-m DB-225 column using methane negative chemical ionization and collecting ions in selected ionmonitoring mode at m/z 435, 436, and 437 (representing M 0 , M 1 , and M 2 mass isotopomers, respectively). Baseline (unenriched) DNA standards were measured concurrently to correct for abundance sensitivity.
The enrichment of the M 1 ion greater than natural abundance in the adipose samples (preadipocytes and adipocytes) was determined by subtracting the M 1 value in the standard from the M 1 value in the sample. The theoretical maximum M 1 enrichment in adipose cells was calculated using mass isotopomer distribution analysis equations (28) At metabolic steady-state (i.e., weight stability), fraction of new cells (f) can represent both adipogenic and replacement rates, providing an estimate of adipose cell turnover (i.e., the fraction of newly formed cells and cell deaths). In non-steadystate conditions, f denotes the formation of adipose cells (i.e., adipogenesis) but might not reflect adipose cell death. Because it is difficult to accurately assess fluctuations in body fat mass or adipocyte number, we have used the noncommittal term "formation (i.e., replacement) rate" to describe the f.
Blood monocytes were taken at 8 weeks and analyzed to represent a (near) completely turned-over cell population. This measurement, used as a reference marker of 2 H 2 O exposure, served to confirm calculations using the theoretical maximum enrichment.
Statistical analysis
A linear repeated measure model was used to estimate the fraction of new preadipocytes and adipocytes over 8 weeks and to determine the independent covariates associated with the f. This model adjusts for fixed effects (age, race, BMI, percentage of body fat, and waist/hip ratio) and random effects (four repeated measures per subject; combination of cell types and depots). The Akaike information criterion (AIC) was the model selection criteria used to determine which set of covariates best describes the data. The AIC combines information about the fit of the data with the number of covariates used. A lower AIC score indicates a better fitting model. Simple associations were examined using Spearman's correlation.
Results
The study population included 52 women (27 black and 25 white women). No statistically significant differences were present between the ethnic groups. The anthropometric and clinical characteristics of all women in the study are listed in Table 1 . The initial analyses showed that the f was not normally distributed (median, 0.104176; range, 0.74465; Shapiro-Wilk, P , 0.0001). Therefore, the f values were log transformed to obtain a normal distribution, denoted as f ln (median, 22.26167; range, 3.79837; Shapiro-Wilk, P = 0.7932). The AIC for models with every combination of covariates (Table 1) was investigated, and f ln by both cell type (adipocyte and preadipocyte) and depot (scABD and scFEM) were included in all models. The model that best described the data (lowest AIC) included BMI, change in body weight, VAT/TAT, IHL, IMCL, and Matsuda index ( Table 2 Initial analyses of f ln between black and white women showed no statistically significant differences (P = 0.65); therefore, race was not included in the final model ( Table 2) . Colinearity between the covariates in the final model was determined to not be an issue, because the correlations were relatively low (|r|,0.40). The covariates BMI, change in body weight, VAT/TAT, and Matsuda index were significantly associated with the overall f ln (i.e., formation of preadipocytes and adipocytes in the scABD and scFEM; Table 2 ). Further analyses and presentation of data focused on simple linear correlations, depicted by cell type and depot, between the f ln and select characteristics associated with impaired metabolic health. First, we assessed how in vivo adipose cellular kinetics correlated with BMI. Adipocyte (P = 0.001) and preadipocyte (P = 0.08; trend) formation (i.e., replacement) rates in the scABD depot were positively associated with the BMI. Similarly, adipocyte (P = 0.006) and preadipocyte (P = 0.02) formation (i.e., replacement) rates in scFEM were also positively correlated.
We also investigated how in vivo kinetics was associated with a change in body weight. Adipocyte (P = 0.03) and preadipocyte (P = 0.01) formation (i.e., replacement) rates in the scABD depot were negatively associated with a change in body weight. Similarly, adipocyte (P = 0.02) and preadipocyte (P = 0.02) formation (i.e., replacement) rates in scFEM were negatively correlated with a change in body weight.
We then assessed how in vivo adipose cell kinetics correlated with visceral adiposity (i.e., VAT/TAT). Figure 1 illustrates that adipocyte (P = 0.02) and preadipocyte (P = 0.16; trend) formation rates in the scABD depot were positively associated with the percentage of VAT/TAT [ Fig. 1(a) and 1(b) ]. Similarly, adipocyte (P = 0.01) and preadipocyte (P = 0.24; trend) formation (i.e., replacement) rates in scFEM were positively correlated [ Fig. 1(c)  and 1(d) ].
We also examined how in vivo cellular kinetics correlated with ectopic lipid deposition, specifically IHL and IMCL. The formation (i.e., replacement) rate of adipocytes (P = 0.65) and preadipocytes (P = 0.96) in the scABD depot was not significantly associated with the percentage of IHL. Likewise, the formation (i.e., replacement) rate of adipocytes (P = 0.23) and preadipocytes (P = 0.42) in the scFEM depot was not significantly associated with the percentage of IHL. Similarly, the formation (i.e., replacement) rate of adipocytes (P = 0.65) and preadipocytes (P = 0.70) in the scABD depot was not associated with the percentage of IMCL. The formation (i.e., replacement) rate of adipocytes (P = 0.14; trend) and preadipocytes (P = 0.05; trend) in the scFEM depot showed a trend toward an association with the percentage of IMCL.
Finally, we examined how in vivo adipose cellular kinetics was associated with insulin sensitivity, as assessed using the Matsuda index. Figure 2 demonstrates that the formation (i.e., replacement) of adipocytes [ Fig.  2(a) ; P , 0.0001] and preadipocytes [ Fig. 2(b) ; P = 0.02] in the scABD depot was negatively associated with insulin sensitivity. In addition, the formation (i.e., replacement) of adipocytes [ Fig. 2(c) ; P = 0.0001] and preadipocytes [ Fig. 2(d) ; P = 0.003] in the scFEM depot correlated negatively with insulin sensitivity.
Discussion
Previous analyses of adipocyte morphology in vitro have suggested that impaired hyperplasia, coupled with increased adipocyte hypertrophy, is linked to metabolic dysfunction (29) . Hyperplasia (i.e., many small adipocytes) in the scABD AT was associated with better glucose, insulin, and lipid profiles (5, 30) , and low scABD adipogenic rates were strongly associated with visceral adiposity (31) . Recently, more detailed analyses have demonstrated that insulin resistance and type 2 diabetes mellitus in obese individuals are associated with a greater proportion of small adipocytes (i.e., hyperplasia) (8) (9) (10) (11) , in addition to adipocyte hypertrophy (9, 31) . Furthermore, studies from our laboratory have shown that individuals with a smaller mean adipocyte size at baseline exhibited a greater decline in insulin sensitivity after an 8-week overfeeding intervention (7). In line with these studies, our present data are in contrast to the existing AT expandability hypothesis and have demonstrated, for the first time to the best of our knowledge, that higher in vivo formation (i.e., replacement) rates of preadipocytes and adipocytes are positively associated with BMI and visceral adiposity and with decreased insulin sensitivity, all correlates of impaired metabolic health (24, 32, 33) . Additional data have demonstrated that in vivo adipose kinetics (f ln ) also correlate with the number of risk factors for metabolic syndrome present in the women. Adipocyte (P = 0.01) and preadipocyte (P = 0.03) formation (i.e., replacement) rates in the scABD depot were positively associated with the number of metabolic syndrome risk factors. Similarly, adipocyte (P = 0.04) and preadipocyte (P = 0.03) formation (i.e., replacement) rates in scFEM were positively correlated. We originally hypothesized that enhanced in vivo adipogenesis in the subcutaneous AT would be associated with favorable metabolic health outcomes. However, our compelling data suggest the contrary and imply that an alternative manner of impaired adipose expansion could be at work. One hypothesis is the presence of abundant small adipocytes with a decreased capacity to sufficiently expand and store lipid, contributing to metabolic dysfunction. Alternatively, our data could suggest enhanced adipogenesis accompanied by increased adipose cell death. Our data revealed that a change in body weight was significantly associated with the overall f ( Table 2 ; P = 0.01). As described in the Results section, the adipose cell formation (i.e., replacement) rates in the scABD and scFEM depots were negatively associated with a change in body weight, suggesting that women with greater weight gain had lower in vivo adipogenesis. This inverse correlation might support a hypertrophic pattern of adipose expansion, in addition to hyperplasia, in women who accumulated more weight during the study period. Alternatively, this finding might suggest that hyperplastic expansion is achieved through a combination of cell formation and cell death. The body weight change in these subjects during the 8-week period was on average 20.77 6 2 kg. This equates to a minimal change in total body fat (,1.5% of total body mass). Accordingly, the formation of new adipose cells was likely balanced by the death of adipose cells. Hence, in this population of women with obesity at near metabolic steady-state, the fraction of newly formed adipose cells was similar to the fraction of cell deaths, revealing a measure of adipose cell turnover or replacement. Although not directly assessed in the present analysis, the 2 H-labeling protocol can be applied to quantitatively measure adipose cell death.
Only one other research group has assessed adipocyte turnover in humans via the incorporation of 14 C (15). They reported that the in vivo production of scABD adipocytes was positively correlated with more hyperplastic expansion, as predicted by the morphology index (5) . In addition, they suggested that individuals with higher hyperplastic expansion had a more favorable metabolic profile (i.e., lower homeostatic model assessment index and fasting insulin). Our present data challenge the findings of Arner et al. (5) , and the differences can be attributed to the methods used to estimate adipose cell turnover in each study. Our analysis was strengthened by the use of the 2 H-labeling method, a validated protocol to directly measure cell proliferation (17) . In addition, our study approach did not indirectly characterize individuals as having primarily hypertrophic or hyperplastic expansion according to the mean adipocyte size but used direct quantitative estimates of adipose cell formation to correlate with metabolic outcomes. This represents a strength of our analysis, because large intraand intersubject variability exists in adipocyte size and number in humans. Overall, to the best of our knowledge, we present the first analysis of quantitative assessments of in vivo adipose cellular kinetics in relation to markers of metabolic health in humans. Our data strongly suggest that individuals with higher adipose cell replacement have a higher BMI, more intra-abdominal lipid, and decreased insulin sensitivity.
Ectopic fat deposition within the liver (IHL) and skeletal muscle (IMCL and EMCL) are accepted determinants of insulin resistance in humans (34, 35) . The percentage of IHL and percentage of IMCL, but not the percentage of EMCL, were included in the final model as plausible correlates of the overall f (Table 2 ). However, after adjusting for the other covariates in the model, neither the percentage of IHL (P = 0.12) nor the percentage of ICML (P = 0.84) had a statistically significant association with f. Likewise, these correlations were not statistically significant when assessed individually by cell type and depot. Owing to the variability of the percentage of IHL in the women, we conducted an additional AIC analysis with the data from 50 women, excluding 2 extreme outliers (15% and 28% IHL), which resulted in an even weaker correlation of the percentage of IHL with f (P = 0.636). These associations were also not statistically significant when assessed individually by cell type and depot. Although the deposition of fat in ectopic sites, in contrast to subcutaneous AT, is highly associated with metabolic health risk, our data demonstrated an important relationship of visceral adiposity, but not liver or skeletal muscle lipid, with in vivo preadipocyte and adipocyte turnover. More studies are needed in populations with varying degrees of ectopic lipid deposition to ascertain the influence of in vivo adipose cellular kinetics on ectopic fat.
The parameters of the lipid profile (triglycerides, lowdensity lipoprotein, high-density lipoprotein/total cholesterol) and mean BP did not correlate with the overall f ( Table 2) . Our data have convincingly demonstrated a strong relationship between in vivo adipogenesis (i.e., replacement) and metabolic aberrations of obesity but not with traditional cardiovascular disease risk factors.
Given the opposing associations of upper vs lower body AT with metabolic health, our inclusion of scABD and scFEM depots provided a more comprehensive view of subcutaneous adipose cell kinetics and represents an additional strength of our study. Our data suggest that correlations between f and various metabolic outcomes display a similar trend in the scABD and scFEM depots. However, one cannot eliminate the possibility of depot differences in different study populations or after interventions that induce dynamic changes in AT expansion.
One limitation of the present study was that we did not assess the cellular kinetics in VAT. Given the strong correlation between the cellular kinetics of subcutaneous AT and VAT content, as observed in our analysis, and the recognized link between VAT and adverse metabolic consequences (36) , further investigations of VAT cell turnover are necessary. Our study included only women. Therefore, our results cannot be extrapolated to men, because sex differences in body fat distribution and insulin sensitivity have been reported (37) .
It is important to note that our data reflect correlations between the covariates and do not infer cause-and-effect relationships. Hence, we could not determine whether adipose cell turnover is the cause or consequence of the observed markers, nor could we assess the metabolic response to cellular kinetics that would occur during AT expansion and weight change. Nevertheless, our present data implicate an important prospective role for in vivo adipose cell kinetics in the pathology of metabolic disorders.
In conclusion, we present evidence that in vivo adipose cell kinetics in women with obesity is highly associated with unfavorable markers of metabolic health, namely BMI, VAT, and impaired insulin sensitivity. Numerous reports have suggested that AT expandability is a key determinant of obesity-associated metabolic dysregulation. Our analysis has provided insight into the cellular mechanisms underlying AT dynamics in obese humans. Additional investigations, including ones that assess the metabolic response to a variety of interventions (i.e., overfeeding, caloric restriction, exercise training, pharmacological treatments) are necessary to better characterize how adipose turnover is involved in the pathogenesis of obesity-related diseases.
